New Zealand Pharmaceuticals Ltd is pleased to announce that the U.S. patent 8,420,063, entitled “N-acetyl mannosamine as a therapeutic agent” was issued on April 2, 2013. The invention relates to...

The application of N-acetylmannosamine to the mammalian cell culture production of recombinant human glycoproteins   Selwyn C Yorke   Keywords: N-acetylmannosamine, sialylation, glycoproteins.   This mini-review covers recent developments in the understanding, role and value of...

New Zealand Pharmaceuticals Ltd is proud to announce that is has been audited by TELARC and achieved its first ISO 14001 certification. In 2010, NZP implemented a specific program within...

  We are pleased to announce that Dextra laboratories Ltd and NZP will attend Informex USA 2013 in Anaheim CA, on February 20 & 21, 2013.   Please arrange to meet us by...

NZP is pleased to announce that Dextra has just received the French Ministére de L’Enseignement Supérieur et de la Recherche Tax Credit certificate.  This is good news for any business...

New Zealand Pharmaceuticals Ltd Celebrates One Million Hours of No Lost Time New Zealand Pharmaceuticals Ltd (NZP), a global leader in Bile Acids manufacturing has proven itself to be a model...

There is confusion in some circumstances with the very similar names of two quite different medical disorders; Inclusion Body Myositis and Hereditary Inclusion Body Myopathy. This press release is to...

New research published on potential mannosamine therapy for HIBM (GNE myopathy) and kidney glomerular disease   “Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy”,...

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health...

New Zealand Pharmaceuticals Ltd Announces a phase I clinical trial using DEX-M74 to treat a rare degenerative muscle disease Palmerston North, New Zealand, September 26, 2012 — New Zealand Pharmaceuticals Ltd...

There is growing interest in the research community regarding new agonists that activate the FXR, LXR and TGR5 nuclear receptors. These receptors are linked to a wide range of disorders from...

We are pleased to announce that New Zealand Pharmaceuticals Ltd and Dextra will attend BIO 2012 in Boston, MA, on June 18-2130, 2012. Please arrange to meet us by direct email...

National Human Genome Research Institute (NHGRI) (Bethesda, MD; www.genome.gov) and New Zealand Pharmaceuticals Ltd (NZP) (Palmerston North, New Zealand; www.nzp.co.nz) have partnered on a drug development project. The goal is...

NZP’s CEO, Andy Lewis, will be a plenary speaker at the NZ Bio conference on Tuesday 27 March 2012, www.nzbio2012.co.nz to discuss the development of NZP’s new drug candidate, DEX-M74...

The U.S. National Institutes of Health Clinical Center (NIH CC) in Bethesda, Maryland, U.S. is running a natural history study on patients with hereditary inclusion body myopathy (HIBM).  This study...

New Zealand Pharmaceuticals Ltd receives Orphan Drug Designation from the U.S. Food and Drug Administration for DEX-M74, a Treatment for Hereditary Inclusion Body Myopathy (HIBM) Palmerston North, New Zealand, December 15,...

There is a groundswell of interest in the research community regarding new agonists that activate the FXR, LXR and TGR5 nuclear receptors. These receptors are linked to a wide range...

New Zealand Pharmaceuticals Announces Collaboration with the NHGRI to Develop DEX-M74 as a Treatment for Hereditary Inclusion Body Myopathy (HIBM)

NZP 300-level Bursary The Bursary was awarded jointly to Heather Jameson and David Nixon. Both these candidates attended secondary school in Palmerston North and then chose to study at Massey University...

The end of New Zealand Pharmaceuticals' wastewater discharge directly into the Manawatu River is a milestone for the waterway.

NZP has always endeavoured to engage in sustainable business practices, recognizing that potentially, without intervention, demand will eventually exceed supply of eco-system resources. Interestingly, NZP itself was built on the...